Zentalis Pharmaceuticals (ZNTL) Key Ratios
$4.03
As on 08-Sep-2026 15:38EDT
Market cap
$378 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -- | -- | -- | -- | -- |
| EBIT | -119.63 | -121.68 | -9.46 | 7.63 | 0.69 |
| Net Profit | -119.61 | -188.90 | -7.44 | 11.52 | -18.55 |
| EPS | -119.61 | -196.00 | -8.41 | 14.11 | 7.72 |
| Book Value | -- | -- | -36.27 | -25.58 | -17.15 |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-25 | Dec-24 |
| EBIT-Margin
| -278.02 | -278.02 | -- | -- | -278.02 |
| Net Margin
| -- | 567.68 | -- | -- | -- |
| Return on equity
| -53.15 | -53.20 | -97.21 | -49.53 | -42.83 |
| Return on Capital
| -47.39 | -47.88 | -- | -43.13 | -38.44 |
| Return on Assets
| -41.31 | -41.60 | -54.34 | -38.11 | -33.42 |
| Debt to Equity (x)
| -- | -- | 0.00 | 0.18 | 0.13 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
-43.13
|
-38.44
|
-60.61
|
-53.16
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
-97.21
Lower than Peers by 56.87
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
-97.21
|
-49.53
|
-42.83
|
-67.09
|
-59.37
|
|
Peer Median
|
-40.33
|
--
|
--
|
--
|
--
|
ROA
-54.34
Lower than Peers by 23.10
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
-54.34
|
-38.11
|
-33.42
|
-52.39
|
-46.18
|
|
Peer Median
|
-31.24
|
--
|
--
|
--
|
--
|
EBIT Margin
--
--
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
--
|
-278.02
|
--
|
--
|
|
Peer Median
|
-82.60
|
--
|
--
|
--
|
--
|
Net Margin
--
--
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
--
|
-245.96
|
--
|
1,454.40
|
|
Peer Median
|
-91.30
|
--
|
--
|
--
|
--
|
Revenue Growth
--
--
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
-1.00
|
--
|
--
|
--
|
|
Peer Median
|
54.03
|
--
|
--
|
--
|
--
|
EBIT Growth
-9.46
Lower than Peers by 8.44
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
-9.46
|
22.64
|
24.71
|
-5.95
|
-13.12
|
|
Peer Median
|
-1.02
|
--
|
--
|
--
|
--
|
Net Profit Growth
-7.44
Higher than Peers by 0.09
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
-7.44
|
17.35
|
43.24
|
-23.39
|
-49.19
|
|
Peer Median
|
-7.53
|
--
|
--
|
--
|
--
|
EPS Growth
-8.41
Lower than Peers by 22.64
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
-8.41
|
0.18
|
0.44
|
-0.03
|
-0.13
|
|
Peer Median
|
14.23
|
--
|
--
|
--
|
--
|
Book Value Growth
-46.38
Lower than Peers by 36.25
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
-46.38
|
--
|
--
|
--
|
--
|
|
Peer Median
|
-10.13
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
--
--
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
0.18
|
0.13
|
0.10
|
0.11
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.03
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
0.03
|
0.02
|
0.01
|
0.01
|
0.00
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
4.82
Lower than Peers by 0.99
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
4.82
|
6.93
|
7.32
|
7.16
|
7.98
|
|
Peer Median
|
5.81
|
--
|
--
|
--
|
--
|
Quick Ratio
4.82
Lower than Peers by 0.88
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
4.82
|
--
|
--
|
--
|
8.10
|
|
Peer Median
|
5.70
|
--
|
--
|
--
|
--
|
Interest Coverage
--
--
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
--
|
--
|
--
|
-91.26
|
|
Peer Median
|
-2.09
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
--
--
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
--
|
7.42
|
--
|
--
|
|
Peer Median
|
19.01
|
--
|
--
|
--
|
--
|
Asset Turnover
--
--
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
--
|
0.14
|
--
|
--
|
|
Peer Median
|
0.06
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
--
|
27.09
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
--
|
--
|
-1,851.49
|
-1,470.22
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
3,619.39
|
3,168.52
|
3,441.21
|
2,924.69
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
-0.71
|
-1.30
|
-3.67
|
-5.04
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Price / Book Value
2.45
Lower than Peers by 2.88
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
2.45
|
0.45
|
0.64
|
2.45
|
2.75
|
|
Peer Median
|
5.33
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
EV/EBITDA
-2.31
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
-2.31
|
0.76
|
0.60
|
-2.56
|
-3.44
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
378
Higher than Peers by 236
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-25
|
Dec-24
|
Dec-23
|
Dec-22
|
|---|---|---|---|---|---|
|
Zentalis Pharmaceuticals (ZNTL)
|
378
|
--
|
--
|
--
|
--
|
|
Peer Median
|
142
|
--
|
--
|
--
|
--
|